Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaci, D, A Kimball, P Foley, Y Poulin, E Levi, R Chen, and S R Feldman. 2017. “Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Improves Patient-Reported Outcomes in the Treatment of Moderate to Severe Psoriasis: Results of Two Phase III Randomized, Controlled Trials.”. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (3): 498-506.